Entendu dans les médias

June 17, 2021
MARLBOROUGH, Mass.–(BUSINESS WIRE)– Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, has completed its previously announced acquisition of Mobidiag Oy, an innovator in near-patient, acute care molecular diagnostic testing, for an enterprise value of approximately $808 million.

“Closing the acquisition of Mobidiag enables us to become a broader, more diversified global diagnostics leader,” said Jan Verstreken, group president, international at Hologic. “Together, we can accelerate development and adoption of Mobidiag’s innovative products globally and drive Hologic’s growth.”

The article features the successful evaluation of Novodiag® CarbaR+ conducted by Nottingham University Hospitals, NHS Trust, Clinical Microbiology, Queen’s Medical Centre.

Shova Sharma, Associate Practitioner & Experimental Lead of the evaluation and Su Sewaa, Deputy Service Manager of NUH QMC have recently evaluated the test and their results are featured in this month´s Biomedical Scientist issue. NUH Clinical Microbiology will be publishing poster of the evaluation in October 2019 at EMMD in the Netherlands.

Delighted to announce that Mobidiag´s Novodiag® CarbaR+ test has been shortlisted for Best Technological Innovation: Diagnostics at the 2019 Medtech Insight Awards.

“This Award will recognize the efforts of an individual, team, or company that developed an innovative medical device or diagnostic that makes significant contributions to advancing patient treatment. The judges will be looking for the product that represents the most innovative new approach to care by addressing an unmet clinical need; by changing the practice of health care to be more effective, efficient or less error-prone; or by expanding technology to new patient populations.”

Our CEO Tuomas Tenkanen has been interviewed by the Finnish Magazine Talouselämä to talk about the exciting latest news at Mobidiag.
The article features Mobidiag innovative solutions to fight against superbacteria and antibiotic resistances, as well as the latest 10 million euros investment from Chinese company Autobio Diagnostics.

Learn more about the agreement announced last December.

Read full article: in Finnish, See poster